Poor patient adherence to medication treatments and solutions for overcoming compliance barriers as illustrated by antiplatelet therapy
DOI: 10.32364/2587-6821-2023-7-1-56-61
F.T. Ageev, M.D. Smirnova, T.V. Fofanova
National Medical Research Center of Cardiology, Moscow, Russian Federation
The article is focused on the issues of poor patient adherence to medication treatments, including antiplatelet drugs, its reasons, and solutions for overcoming compliance barriers. As of today, treatment adherence remains low leading to a higher risk of cardiovascular complications. Poor adherence to acetylsalicylic acid (ASA) treatment is mainly linked to a relatively frequent development of gastrointestinal side effects. The solutions for overcoming this problem include the use of lowest effective doses and the development of different acetylsalicylic acid (ASA) formulations: enteric coated and buffered. The efficacy and safety of these formulations are compared in the article. Buffered formulation (e.g. ASA + magnesium hydroxide) is similar to plain ASA as regards its antiplatelet activity and the prevalence of "aspirin-resistance", while its intake is associated with a lower risk of enteropathy and gastropathy as compared to plain and even enteric coated ASA. This is particularly important for patients with obesity and diabetes mellitus, as these conditions are associated with an affected rate of absorption from the small intestine. Based on the study findings a conclusion is made that buffered ASA should be the preferred formulation for use. The literature review is illustrated by a clinical case.
Keywords: chronic ischemic heart diseases, secondary prevention, adherence to therapy, acetylsalicylic acid, antiaggregant therapy, acetylsalicylic acid buffered and enteric coated formulations, aspirin-resistance.
For citation: Ageev F.T., Smirnova M.D., Fofanova T.V. Poor patient adherence to medication treatments and solutions for overcoming compliance barriers as illustrated by antiplatelet therapy. Russian Medical Inquiry. 2023;7(1):56–61 (in Russ.). DOI: 10.32364/2587-6821-2023-7-1-56-61.
About the authors:
Fail T. Ageev — Dr. Sc. (Med.), Professor, Head of the Department of Treatment and Diagnostic Technologies of A.L. Myasnikov Research Institute of Clinical Cardiology, National Medical Research Center of Cardiology; 15A, 3rd Cherepkovskaya str., Moscow, 121552, Russian Federation; ORCID iD 0000-0003-4369-1393.
Maria D. Smirnova — Dr. Sc. (Med.), senior researcher of the Department of Treatment and Diagnostic Technologies of A.L. Myasnikov Research Institute of Clinical Cardiology, National Medical Research Center of Cardiology; 15A, 3rd Cherepkovskaya str., Moscow, 121552, Russian Federation; ORCID iD 0000-0001-6515-3882.
Tatyana V. Fofanova — Dr. Sc. (Med.), senior researcher of the Department of Treatment and Diagnostic Technologies of A.L. Myasnikov Research Institute of Clinical Cardiology, National Medical Research Center of Cardiology; 15A, 3rd Cherepkovskaya str., Moscow, 121552, Russian Federation; ORCID iD 0000-0002-3321-2902.
Contact information: Maria D. Smirnova, e-mail: naliya1@yandex.ru.
Financial Disclosure: the article is prepared with support of "Nizhpharm" JSC (the STADA Group of Companies).
Conflict of interests: materials provided by "Nizhpharm" JSC (the STADA Group of Companies) were used for writing the overview section of the article. The authors' opinion may differ from the company's opinion.
Received 12.01.2023.
Revised 06.02.2023.
Accepted 27.02.2023.
2. Chowdhury R., Khan H., Heydon E. et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J. 2013;34(38):2940–2948. DOI: 10.1093/eurheartj/eht295.
3. Rojas-Fernandez C.H., Kephart G.C., Sketris I.S., Kass K. Underuse of acetylsalicylic acid in individuals with myocardial infarction, ischemic heart disease or stroke: data from the 1995 population-based Nova Scotia Health Survey. Can J Cardiol. 1999;15(3):291–296. PMID: 10202192.
4. Zaninelli A., Kaufholz C., Scwappach D. Physicians attitudes toward post-MI aspirin prophylaxis: findings from an online questionnaire in Europe and Latin America. Postgrad Med. 2009;2(6):44–53. DOI: 10.3810/pgm.2009.11.2070.
5. Горбунов В.М. Проблемы приверженности больных, перенесших инфаркт миокарда, профилактическому приему ацетилсалициловой кислоты. Результаты исследования ACT. Кардиоваскулярная терапия и профилактика. 2010;9(5):95–101. [Gorbunov V.M. Compliance to preventive aspirin therapy in patients after acuter myocardial infarction. ACT Study results. Cardiovascular Therapy and Prevention. 2010;9(5):95–101 (in Russ.)].
6. Biondi-Zoccai G., Wu Y., Serrano C.V. Jr. et al. Aspirin underuse, non-compliance or cessation: definition, extent, impact and potential solutions in the primary and secondary prevention of cardiovascular disease. Int J Cardiol. 2015;182:148–154. DOI: 10.1016/j.ijcard.2014.12.091.
7. Herlitz J., Tóth P.P., Naesdal J. Low-dose aspirin therapy for cardiovascular prevention: quantification and consequences of poor compliance or discontinuation. Am J Cardiovasc Drugs. 2010;10(2):125–141. DOI: 10.2165/11318440-000000000-00000.
8. Antithrombotic Trialists' (ATT) Collaboration; Baigent C., Blackwell L. et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373(9678):1849–1860. DOI: 10.1016/S0140-6736(09)60503-1.
9. Вовк Е.И., Наумов А.В., Чудаков С.Ю. Эффективная и безопасная антиагрегантная терапия в общемедицинской практике. Врач скорой помощи. 2006;1:51–59. [Vovk E.I., Naumov A.V., Chudakov S.Yu. Effective and safe antiplatelet therapy in general medical practice. Vrach skoroy pomoshchi. 2006;1:51–59 (in Russ.)].
10. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71–86. DOI: 10.1136/bmj.324.7329.71.
11. Juul-Möller S., Edvardsson N., Jahnmatz B. et al. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. The Swedish Angina Pectoris Aspirin Trial (SAPAT) Group. Lancet. 1992;340(8833):1421–1425. DOI: 10.1016/0140-6736(92)92619-q.
12. Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. The SALT Collaborative Group. Lancet. 1991;338(8779):1345–1349. PMID: 1682734.
13. Hansson L., Zanchetti A., Carruthers S.G. et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351(9118):1755–1762. DOI: 10.1016/s0140-6736(98)04311-6.
14. Lanas A., Scheiman J. Low-dose aspirin and upper gastrointestinal damage: epidemiology, prevention and treatment. Curr Med Res Opin. 2007;23(1):163–173. DOI: 10.1185/030079907X162656.
15. Chowdhury A., Ganguly G., Chowdhury D. et al. Gastro-duodenal mucosal changes associated with low-dose aspirin therapy: a prospec-tive, endoscopic study. Indian J Gastroenterol. 2001;20(6):227–229. PMID: 11817775.
16. Баркаган З.С., Котовщикова Е.Ф. Сравнительный анализ основных и побочных эффектов различных форм ацетилсалициловой кислоты. Клиническая фармакология и терапия. 2004;13(3):1–4. [Barkagan Z.S., Kotovshchikova E.F. Comparative analysis of the main and side effects of various forms of acetylsalicylic acid. Klinicheskaya farmakologiya i terapiya. 2004;13(3):1–4 (in Russ.)].
17. Cox D., Maree A.O., Dooley M. et al. Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers. Stroke. 2006;37(8):2153–2158. DOI: 10.1161/01.STR.0000231683.43347.
18. Lavie C.J., Howden C.W., Scheiman J., Tursi J. Upper Gastrointestinal Toxicity Associated With Long-Term Aspirin Therapy: Consequences and Prevention. Curr Probl Cardiol. 2017;42(5):146–164. DOI: 10.1016/j.cpcardiol.2017.01.006.
19. Abrignani M.G., Gatta L., Gabrielli D. et al. Gastroprotection in patients on antiplatelet and/or anticoagulant therapy: a position paper of National Association of Hospital Cardiologists (ANMCO) and the Italian Association of Hospital Gastroenterologists and Endoscopists (AIGO). Eur J Intern Med. 2021;85:1–13. DOI: 10.1016/j.ejim.2020.11.014.
20. Остроумова О.Д. Возможности применения кардиомагнила у пациентов с сахарным диабетом. РМЖ. 2004;5:350–354. [Ostroumova O.D. Possibilities of using cardiomagnil in patients with diabetes mellitus. RMJ. 2004;5:350–354 (in Russ.)].
21. Takada M., Fujimoto M., Hosomi K. Difference in risk of gastrointestinal complications between users of enteric-coated and buffered low-dose aspirin. Int J Clin Pharmacol Ther. 2014;52(3):181–191. DOI: 10.5414/CP201997.
22. Endo H., Sakai E., Higurashi T. et al. Differences in the severity of small bowel mucosal injury based on the type of aspirin as evaluated by capsule endoscopy. Dig Liver Dis. 2012;44(10):833–838. DOI: 10.1016/j.dld.2012.05.016.
23. Hirata Y., Kataoka H., Shimura T. et al. Incidence of gastrointestinal bleeding in patients with cardiovascular disease: buffered aspirin versus enteric-coated aspirin. Scand J Gastroenterol. 2011;46(7–8):803–809. DOI: 10.3109/00365521.2011.568522.
24. Ломакин Н.В., Русанова А.В., Бурячковская Л.И., Вершинина М.Г. Сравнение антиагрегантной эффективности разных форм ацетилсалициловой кислоты. Сердце: журнал для практикующих врачей. 2014;13(4):206–215. [Lomakin N.V., Rusanova A.V., Buryachkovskaya L.I., Vershinina M.G. Comparison of the antiplatelet efficacy of different forms of acetylsalicylic acids. Serdtse: zhurnal dlya praktikuyushchikh vrachey. 2014;13(4):206–215 (in Russ.)].
25. Бурячковская Л.И., Ломакин Н.В., Русанова А.В., Вершинина М.Г. Резистентность к ацетилсалициловой кислоте: причины и следствие. Сердце: журнал для практикующих врачей. 2016;15(5):379–388. DOI: 10.18087/RHJ.2016.5.2261. [Buryachkovskaya L.I., Lomakin N.V., Rusanova A.V., Vershinina M.G. Acetylsalicylic acid resistance: Causes and effects. Russian Heart Journal. 2016;15(5):379–388 (in Russ.)]. DOI: 10.18087 / rhj.2016.5.2261.
26. Bhatt D.L., Grosser T., Dong J.F. et al. Enteric Coating and Aspirin Nonresponsiveness in Patients With Type 2 Diabetes Mellitus. J Am Coll Cardiol. 2017;69(6):603–612. DOI: 10.1016/j.jacc.2016.11.050.
This work is licensed under a Creative Commons «Attribution» 4.0 License.
